Cases of overdoses caused by over-consumption of opioids like the drug OxyContin have been increasing of late. This sparked concern among health organizations about the growing addiction rates on substances that are deemed legal. Scientists have recently created vaccines for at least two types of opioids, which helps to prevent overdose. Interestingly enough, it would appear that they did so by accident.
According to The Science Explorer, the purpose of the study was simply to create a means of mitigating the reward effect that is commonly attributed to opioids. The substances basically dull the pain or induce a feeling of satisfaction in patients, and this is the reason that many become addicted to them.
In doing so, the scientists came across an interesting side-effect of also preventing drug overdose via opioids. Kim D. Janda of the Skaggs Institute for Chemical Biology at TSRI says that this discovery has huge implications in reducing death rates among opioid addicts.
“We saw both blunting of the drug's effects and, remarkably, prevention of drug lethality," Janda said. "The protection against overdose death was unforeseen but clearly of enormous potential clinical benefit."
The study was conducted using animal test subjects and now the scientists are moving to apply their research on humans, Phys.org reports. The vaccine basically works the same way as every other vaccine does. It enables the natural immune responses of the human body, which detects harmful substances and fights them.
In the case of viral vaccines, mild versions of microorganisms are introduced into the body, which helps the immune system develop an effective countermeasure against the real thing. For the opioid vaccine, the scientists took the same approach, but this time adding a molecule that basically signals the body that the opioid is an invading force. This activates the body’s defense mechanisms, eliminating the substance before it reaches the brain.


Moderna Short Sellers Hit With $4.8 Billion Loss as Stock Soars
Novartis M&A Strategy Faces Investor Scrutiny After Drug Setbacks
US-Backed Pediatric HIV Treatment Drops After Foreign Aid Changes, Study Finds
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal
FDA Investigates New Cyclospora Outbreak as U.S. Cases Continue to Rise
France Battles Mediterranean Wildfires as Heatwave Fuels Fire Risk
The government is ‘doubling down’ on its social media ban. But bigger penalties for platforms aren’t enough
GLP-1 Weight-Loss Drug Use Surges Among U.S. Children
France Keeps Top Health Alert as Officials Brace for Another Heatwave
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline
Venezuela Earthquake Health Risks Rise as Disease Monitoring Intensifies
SK Biopharmaceuticals Secures Global Rights to Biohaven Epilepsy Drug Opakalim
Trump Administration Bars U.S. Travelers From Congo Flights Amid Ebola Outbreak
3 clinical-grade skincare creams you really shouldn’t buy online 



